| Florida Eye Clinic P A | |
|
160 Boston Ave, Altamonte Springs, FL 32701-4706 | |
| (407) 834-7776 | |
| (407) 834-0973 |
| Full Name | Florida Eye Clinic P A |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 160 Boston Ave, Altamonte Springs, Florida |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417921180 | NPI | - | NPPES |
| 208488100 | Medicaid | FL |
| Provider Name | Naazli Shaikh |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1467416073 PECOS PAC ID: 8729971072 Enrollment ID: I20040203000026 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Michael T Cady |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1073503983 PECOS PAC ID: 8426045303 Enrollment ID: I20040504001402 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Catherine Wang |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1306837562 PECOS PAC ID: 7517947401 Enrollment ID: I20040721001502 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Alvaro Patino |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1750357380 PECOS PAC ID: 5799756789 Enrollment ID: I20040804000450 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Thomas O Steedle |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1548251515 PECOS PAC ID: 3173626355 Enrollment ID: I20070308000066 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Jayakumar Ananthan-nair |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1912971151 PECOS PAC ID: 0749353993 Enrollment ID: I20080721000649 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | James Jochum |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1427058213 PECOS PAC ID: 6002995982 Enrollment ID: I20080827000560 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Myhanh T Nguyen |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1033314703 PECOS PAC ID: 9537269824 Enrollment ID: I20090210000569 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Harry R. Pappas |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1457342560 PECOS PAC ID: 9133021579 Enrollment ID: I20100201000749 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | David A. Grubbs |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1619968633 PECOS PAC ID: 6406999663 Enrollment ID: I20100210000403 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Ross A Parks |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1447251277 PECOS PAC ID: 8820177702 Enrollment ID: I20100329000752 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Alice Sterling |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1588655542 PECOS PAC ID: 9234265711 Enrollment ID: I20100414000192 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | David S Letbetter |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1578763983 PECOS PAC ID: 3476725615 Enrollment ID: I20130903000515 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Michelle Cho |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1730349192 PECOS PAC ID: 5799941274 Enrollment ID: I20140924002102 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Michael A Warner |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1265458293 PECOS PAC ID: 3274431499 Enrollment ID: I20151121000193 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Bradley Shoss |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1013203272 PECOS PAC ID: 1557673803 Enrollment ID: I20160831002328 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Margi A Patel |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1538416177 PECOS PAC ID: 4183872542 Enrollment ID: I20161115000721 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Kerry Hyman |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1770019457 PECOS PAC ID: 7012285521 Enrollment ID: I20170623001783 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Cristina Sandoval |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1730615410 PECOS PAC ID: 8527336064 Enrollment ID: I20170624000190 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Samantha Xavier |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1316240690 PECOS PAC ID: 4880831080 Enrollment ID: I20171122001126 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Stephanie Hoatson |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1477940641 PECOS PAC ID: 2961743901 Enrollment ID: I20190401001636 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Sarina Mahesh Amin |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1073950119 PECOS PAC ID: 4284877515 Enrollment ID: I20190429000880 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Flana Rose Levando |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1194341248 PECOS PAC ID: 8820406739 Enrollment ID: I20210414000576 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Jush Patel |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1235707597 PECOS PAC ID: 1951794130 Enrollment ID: I20220210002747 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Devin Singh |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1609150895 PECOS PAC ID: 0143471532 Enrollment ID: I20220223000679 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Son T Ho |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1164656534 PECOS PAC ID: 6800272071 Enrollment ID: I20220927000244 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Mary Nguyen |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1558038398 PECOS PAC ID: 9335515857 Enrollment ID: I20221024002591 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Haijiang Lin |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1255599866 PECOS PAC ID: 0941453757 Enrollment ID: I20230125003536 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Provider Name | Tal Manor Kazam |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1316142979 PECOS PAC ID: 7416093513 Enrollment ID: I20230920002705 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Florida Eye Clinic P A 160 Boston Ave, Altamonte Springs, FL 32701-4706 Ph: (407) 834-7776 | Florida Eye Clinic P A 160 Boston Ave, Altamonte Springs, FL 32701-4706 Ph: (407) 834-7776 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.
A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette's protocols can be carried out fully automatically.
› Verified 9 days ago